The loss rate recorded in 2017 was 2% in the Regional Health Promotion Funds for antimalarials and 10% in the health facilities (FOSA) for the medicines that were monitored.
More than 50% of FOSA reported experiencing stock-outs for BCG and RR (Rubella-Measles) antigens. The number of days of stock-outs varied from 19 to 92 days at the central level (EPI) and from 27 to 79 days in the FOSAs: 83.4% of health facilities reported having documents that trace the management of vaccine stocks.